AU2021383613A1 - Inhaled imatinib for pulmonary hypertension field - Google Patents

Inhaled imatinib for pulmonary hypertension field Download PDF

Info

Publication number
AU2021383613A1
AU2021383613A1 AU2021383613A AU2021383613A AU2021383613A1 AU 2021383613 A1 AU2021383613 A1 AU 2021383613A1 AU 2021383613 A AU2021383613 A AU 2021383613A AU 2021383613 A AU2021383613 A AU 2021383613A AU 2021383613 A1 AU2021383613 A1 AU 2021383613A1
Authority
AU
Australia
Prior art keywords
imatinib
substituted
dry powder
composition
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021383613A
Other languages
English (en)
Inventor
John J. Freeman, Jr.
Ajay Keshava
James Mills
Patrick Poisson
Adam Marc Silverstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
United Therapeutics Corp
Original Assignee
Mannkind Corp
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp, United Therapeutics Corp filed Critical Mannkind Corp
Publication of AU2021383613A1 publication Critical patent/AU2021383613A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021383613A 2020-11-17 2021-11-16 Inhaled imatinib for pulmonary hypertension field Pending AU2021383613A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063114781P 2020-11-17 2020-11-17
US63/114,781 2020-11-17
PCT/US2021/059553 WO2022108939A1 (fr) 2020-11-17 2021-11-16 Imatinib inhalé pour le domaine de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
AU2021383613A1 true AU2021383613A1 (en) 2023-07-06

Family

ID=78845039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021383613A Pending AU2021383613A1 (en) 2020-11-17 2021-11-16 Inhaled imatinib for pulmonary hypertension field

Country Status (9)

Country Link
US (1) US20220152025A1 (fr)
EP (1) EP4247337A1 (fr)
JP (1) JP2023550407A (fr)
KR (1) KR20230131179A (fr)
CN (1) CN116916889A (fr)
AU (1) AU2021383613A1 (fr)
CA (1) CA3199324A1 (fr)
IL (1) IL302994A (fr)
WO (1) WO2022108939A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147868A1 (fr) * 2022-02-04 2023-08-10 Justus-Liebig-Universität Giessen Imatinib inhalé pour le traitement de l'hypertension pulmonaire

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
MX2008010721A (es) * 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
BRPI0602338A (pt) * 2006-03-24 2007-12-11 Univ Kyushu Nat Univ Corp compostos orgánicos
CA2654492C (fr) 2006-05-15 2017-06-27 United Therapeutics Corporation Administration de treprostinil utilisant un inhalateur a dose mesuree
EP3281663B8 (fr) 2008-06-13 2022-09-21 MannKind Corporation Inhalateur de poudre sèche alimenté par la respiration pour l'administration de médicaments
DE102008036864A1 (de) 2008-08-07 2010-02-18 Lfk-Lenkflugkörpersysteme Gmbh Stranggepresstes Formteil sowie Verfahren zur Herstellung eines solchen Formteiles
MX2011001668A (es) 2008-08-13 2011-03-25 Novartis Ag Tratamiento de hipertension arterial pulmonar.
MX2011009682A (es) 2009-03-18 2011-10-17 Mannkind Corp Adaptador de inhalador para un aparato de difraccion de laser y metodo para medir la distribucion de tamaño de particula.
EP2496295A1 (fr) 2009-11-03 2012-09-12 MannKind Corporation Appareil et méthode de simulation d'efforts d'inhalation
EP3587404B1 (fr) * 2013-03-15 2022-07-13 MannKind Corporation Compositions de dicétopipérazine microcristallines, procédés de préparation et leur utilisation
WO2015017728A1 (fr) * 2013-07-31 2015-02-05 Windward Pharma, Inc. Composés inhibiteurs de tyrosine kinase en aérosol et leurs utilisations
US20190321290A1 (en) * 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
GB201610044D0 (en) * 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
CA3102967A1 (fr) 2018-06-07 2019-12-12 Mannkind Corporation Composition et procede d'inhalation
JP2022532431A (ja) * 2019-05-16 2022-07-14 エアロベイト セラピューティクス, インコーポレイテッド イマチニブ製剤、その製造および使用

Also Published As

Publication number Publication date
IL302994A (en) 2023-07-01
JP2023550407A (ja) 2023-12-01
CA3199324A1 (fr) 2022-05-27
KR20230131179A (ko) 2023-09-12
CN116916889A (zh) 2023-10-20
EP4247337A1 (fr) 2023-09-27
WO2022108939A1 (fr) 2022-05-27
US20220152025A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
US20220008436A1 (en) Treprostinil administration by inhalation
ES2664175T3 (es) Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa
TWI707700B (zh) 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β2腎上腺素受體激動劑之組成物,及相關方法及系統
ES2266242T3 (es) Tratamiento de enfermedades respiratorias.
ES2745439T3 (es) Partículas micronizadas de agentes activos con baja potencia de dosificación para formulaciones en polvo para inhalación
ES2733998T3 (es) Agente terapéutico específico de enfermedad pulmonar
ES2895687T3 (es) Un procedimiento para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico
JP2017528479A (ja) Rpl554を含む液体吸入製剤
JP2016519160A (ja) 3つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
WO2009090008A1 (fr) Formulation de poudre sèche comprenant un médicament anticholinergique
JP2020023537A (ja) Copdの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ
ES2797073T3 (es) Partículas de inhalación que comprenden una combinación de un anticolinérgico, un corticoesteroide y un beta-adrenérgico
ES2319887T3 (es) Formulacion superfina de salmeterol.
JP2019531308A (ja) 肺線維症の治療のためのクロモリン組成物
US20220152025A1 (en) Inhaled imatinib for pulmonary hypertension
US20110166149A1 (en) Pteridine derivatives for treating respiratory disease
EP2675452A1 (fr) Formulation sans propulseur liquide comprenant un médicament antimuscarinique
ES2232769T3 (es) Composicion farmaceutica que comprende salmeterol y budesonida para el tratamiento de trastornos respiratorios.
KR20180030399A (ko) 네뷸라이저용 조성물
WO2023111930A1 (fr) Poudres pour inhalation et leur procédé de production
WO2024062007A1 (fr) Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
JPWO2004087151A1 (ja) 医薬組成物